| |
Naive* patients |
Experienced patients |
| |
Without
co-infection
(N=195) |
With
co-infection
(N=61) |
p** |
Without
co-infection
(N=624) |
With
co-infection
(N=399) |
p** |
| FPV/r discontinuation |
| |
110 (56.4%) |
40 (65.6%) |
0.20** |
359 (57.5%) |
223 (55.9%) |
0.60** |
| Discontinuation reasons |
| Intolerance |
30 (15.4%) |
16(26.2%) |
0.55 |
123 (19.7%) |
64 (16.0%) |
*** |
| Simplification |
33 (16.9%) |
9(14.8%) |
|
41 (6.6%) |
15(3.8%) |
|
| Death |
3(1.5%) |
0(0%) |
|
1 (0.2%) |
8(2.0%) |
|
| Immuno-virological failure |
19(9.7%) |
5(8.2%) |
|
107 (17.1%) |
58(14.5%) |
|
| Other*** |
25(12.8%) |
10(16.4%) |
|
87(13.9%) |
78(19.5%) |
|
| Reasons for FPV/r discontinuation due to intolerance |
| Digestive side effects |
12 (6.2%) |
10 (16.4%) |
|
51 (8.2%) |
18 (4.5%) |
|
| Biological toxicity**** |
6 (3.1%) |
1 (1.6%) |
|
15 (2.4%) |
7 (1.8%) |
|
| Lipodystrophy |
4 (2.1%) |
0 (0%) |
|
10 (1.6%) |
4 (1.0%) |
|
| Drug intolerance / toxicity |
4 (2.1%) |
1(1.6%) |
|
10 (1.6%) |
8 (2.0%) |
|
| Cutaneous side effects /HSR |
1(0,5%) |
2 (3.2%) |
|
15 (2.4%) |
7 (1.8%) |
|
| Liver toxicity |
1(0.5%) |
1 (1.6%) |
|
1 (0.2%) |
9 (2.2%) |
|
| Neuro-/psychiatric side effects |
0(0%) |
0 (0%) |
|
6 (1.0%) |
1 (0.3%) |
|
| Cardiovascular side effects |
0(0%) |
0(0%) |
|
0(0%) |
3(0.8%) |
|
| Musculoskeletal side effects /myositis |
0(0%) |
0(0%) |
|
3(0.5%) |
0(0%) |
|
| Renal side effects |
0(0%) |
0(0%) |
|
1(0.2%) |
0(0%) |
|
| Other side effects |
2(1.0%) |
1(1.6%) |
|
11(1.8%) |
7(1.8%) |
|
